ArticlePloS one2025
Cerebrospinal fluid haptoglobin levels and outcome after aneurysmal subarachnoid haemorrhage: Evidence from Mendelian randomization.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubarachnoid haemorrhage (SAH) poses a life-threatening risk, contributing to half of all haemorrhagic strokes, with aneurysmal SAH (aSAH) affecting approximately 6 individuals per 100,000 annually. Following aSAH, the influx of plasma haptoglobin into the cerebrospinal fluid (CSF) is insufficient to sequester the released free haemoglobin in the subarachnoid space and avoid its neurotoxic effects. Exogenous administration of haptoglobin could be a therapeutic strategy for improving outcomes after aSAH.
methodsUsing individual level data in the UK Biobank and genetic summary statistics from the largest relevant cohorts, Mendelian randomization analysis was conducted to explore the associations of genetically predicted CSF haptoglobin with the risk of catastrophic aSAH (i.e., fatal aSAH or non-fatal aSAH with at least one of: hemiparesis, aphasia, apraxia, or visual field defects within 7 days) and secondary traits, including stroke-related outcomes and imaging markers of brain swelling.
resultsHigher levels of genetically predicted CSF haptoglobin was associated with lower risk of catastrophic aSAH in multi-ancestry (OR: 0.79, 95% CI: 0.65 to 0.96, p = 0.019) and White British sample analyses (OR: 0.78, 95% CI: 0.63 to 0.95, p = 0.013), while the lack of association with related traits supported effects specific to outcomes after aSAH. A proof-of-concept analysis showing associations of genetically predicted haptoglobin with haemoglobin in plasma validated the proposed mechanism.
conclusionsUsing human genetic data, we provide evidence to support a causal role of higher CSF haptoglobin in improving outcomes after aSAH. However, there was no evidence for an effect on the risk of aSAH or related cerebrovascular events. These findings support haptoglobin as a potential treatment in aSAH to mitigate the neurotoxic effects of free haemoglobin and improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.